Six Novartis oncology compounds are currently in late-stage development
with the potential for registration over the next five years. These
compounds include RAD001 (renal cell carcinoma and other cancers), ASA404
(non-small cell lung cancer), SOM230 (Cushing's disease, refractory
carcinoid tumors and acromegaly), LBH589 (cutaneous T-cell lymphoma and
other cancers), EPO906 (ovarian cancer), and PKC412 (acute myelogenous
leukemia and aggressive systemic mastocytosis).
Other highlights of data to be presented include:
-- The first results from the CALGB trial 79809, of the effects of Zometa
on bone mineral density in premenopausal women who develop ovarian
failure due to adjuvant chemotherapy (Abstract #512: Saturday, May 31,
2008; 5:00 PM-5:15 PM CDT).
-- Results from a Phase II study of bevacizumab and RAD001 in the
treatment of advanced renal cell carcinoma (RCC) (Abstract #5010:
Saturday, May 31, 2008; 2:00-PM-2:15 PM CDT).
-- Data from a multicenter Phase I clinical trial of daily and weekly
RAD001 in combination with weekly paclitaxel and trastuzumab in
patients with Her2-overexpressing metastatic breast cancer with prior
resistance to trastuzumab (Abstract #1003: Monday, June 2, 2008; 4:30
PM-4:45 PM CDT).
-- Analysis of results from a Phase II study of RAD001 in patients with
recurrent endometrial carcinoma (Abstract #5502: Sunday, June 1, 2008;
5:30 PM-5:45 PM CDT).
-- Updated Phase II results on Tasigna in patients with imatinib-resistant
chronic myeloid leukemia in chronic phase (Abstract #7010: Monday, June
2; 10:30 AM - 10:45 AM CDT).
-- Phase II data comparing safety and efficacy between squamous an
|SOURCE Novartis Pharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved